Skip to main content
Premium Trial:

Request an Annual Quote

HTG Molecular Diagnostics to Implement Reverse Stock Split

NEW YORK — HTG Molecular Diagnostics on Monday filed a document with the US Securities and Exchange Commission to effect a 1-for-12 reverse stock split of its outstanding common stock.

The move, which was authorized by the company's stockholders last month, will take effect at the opening of the market on Dec. 21, HTG Molecular said in the filing. It follows a 1-for-15 reverse stock split the company completed in late 2020.

During Tuesday morning trading on the Nasdaq, shares of HTG Molecular were down around 7 percent at $.7664.

About a month ago, the Tucson, Arizona-based company posted a 48 percent year-over-year drop in third quarter revenues as it repositions itself as a drug discovery technology developer.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.